↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "WFRF:(Kalaba M) "

Search: WFRF:(Kalaba M)

Result 1-18 of 18

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Bonanno, PV, et al. (author) Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation 2017 In: Frontiers in pharmacology. - : Frontiers Media SA. - 1663-9812. ; 8, s. 497- Journal article (peer-reviewed)
2.	Godman, B, et al. (author) Personalizing health care: feasibility and future implications 2013 In: BMC medicine. - : Springer Science and Business Media LLC. - 1741-7015. ; 11, s. 179- Journal article (peer-reviewed)
3.	Moorkens, E, et al. (author) Policies for biosimilar uptake in Europe: An overview 2017 In: PloS one. - : Public Library of Science (PLoS). - 1932-6203. ; 12:12, s. e0190147- Journal article (peer-reviewed)
4.	Raschi, E, et al. (author) Mapping the Pro-Arrhythmic Risk of Antipsychotics: Combining Adverse Drug Reactions with Drug Utilization Data across Europe 2012 In: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. - 1053-8569. ; 21, s. 429-429 Conference paper (other academic/artistic)
5.	Raschi, E, et al. (author) Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe 2013 In: PloS one. - : Public Library of Science (PLoS). - 1932-6203. ; 8:11, s. e81208- Journal article (peer-reviewed)
6.	Bajcetic, M, et al. (author) Ongoing Programmes to Reduce the High Rate of Antibiotic Consumption in Serbia; Current Situation and Future Direction 2012 In: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. - 1053-8569. ; 21, s. 98-98 Conference paper (other academic/artistic)
7.	Godman, B, et al. (author) Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? 2015 In: Expert review of clinical pharmacology. - : Informa UK Limited. - 1751-2441 .- 1751-2433. ; 8:1, s. 77-94 Journal article (peer-reviewed)
8.	Godman, B, et al. (author) Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications 2010 In: Expert review of pharmacoeconomics & outcomes research. - : Informa UK Limited. - 1744-8379 .- 1473-7167. ; 10:6, s. 707-722 Journal article (peer-reviewed)
9.	Godman, B, et al. (author) Essential To Review Health Policy Initiatives When Comparing Utilisation Patterns across Countries? 2012 In: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. - 1053-8569. ; 21, s. 56-56 Conference paper (other academic/artistic)
10.	Godman, B, et al. (author) Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications 2014 In: Frontiers in pharmacology. - : Frontiers Media SA. - 1663-9812. ; 5, s. 106- Journal article (peer-reviewed)
11.	Godman, B, et al. (author) Policies to enhance prescribing efficiency in europe: findings and future implications 2011 In: Frontiers in pharmacology. - : Frontiers Media SA. - 1663-9812. ; 1, s. 141- Journal article (peer-reviewed)
12.	Godman, B, et al. (author) Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe? 2010 In: Pharmaceuticals (Basel, Switzerland). - : MDPI AG. - 1424-8247. ; 3:8, s. 2470-2494 Journal article (peer-reviewed)
13.	Poluzzi, E, et al. (author) PRO-ARRHYTHMIC POTENTIAL OF ORAL ANTIHISTAMINES (H1): COMBINING ADVERSE EVENT REPORTS DATA WITH DRUG UTILIZATION DATA ACROSS EUROPE 2018 In: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. - 1053-8569. ; 27:7, s. O10-O11 Conference paper (other academic/artistic)
14.	Poluzzi, E, et al. (author) Pro-arrhythmic potential of oral antihistamines (H1): combining adverse event reports with drug utilization data across Europe 2015 In: PloS one. - : Public Library of Science (PLoS). - 1932-6203. ; 10:3, s. e0119551- Journal article (peer-reviewed)
15.	Poluzzi, E, et al. (author) Pro-Arrhythmic Risk of Oral Antihistamines (H1): Combining Adverse Event Reporting Data with Drug Utilization Data across Europe 2012 In: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. - 1053-8569. ; 21, s. 293-294 Conference paper (other academic/artistic)
16.	Adamski, J, et al. (author) Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers 2010 In: BMC health services research. - : Springer Science and Business Media LLC. - 1472-6963. ; 10, s. 153- Journal article (peer-reviewed)
17.	El-Didamony, Samia E., et al. (author) Melittin alcalase-hydrolysate : a novel chemically characterized multifunctional bioagent; antibacterial, anti-biofilm and anticancer 2024 In: Frontiers in Microbiology. - : Frontiers Media S.A.. - 1664-302X. ; 15 Journal article (peer-reviewed)abstract The prevalent life-threatening microbial and cancer diseases and lack of effective pharmaceutical therapies created the need for new molecules with antimicrobial and anticancer potential. Bee venom (BV) was collected from honeybee workers, and melittin (NM) was extracted from BV and analyzed by urea-polyacrylamide gel electrophoresis (urea-PAGE). The isolated melittin was hydrolyzed with alcalase into new bioactive peptides and evaluated for their antimicrobial and anticancer activity. Gel filtration chromatography fractionated melittin hydrolysate (HM) into three significant fractions (F1, F2, and F3), that were characterized by electrospray ionization mass spectrometry (ESI-MS) and evaluated for their antimicrobial, anti-biofilm, antitumor, and anti-migration activities. All the tested peptides showed antimicrobial and anti-biofilm activities against Gram-positive and Gram-negative bacteria. Melittin and its fractions significantly inhibited the proliferation of two types of cancer cells (Huh-7 and HCT 116). Yet, melittin and its fractions did not affect the viability of normal human lung Wi-38 cells. The IC50 and selectivity index data evidenced the superiority of melittin peptide fractions over intact melittin. Melittin enzymatic hydrolysate is a promising novel product with high potential as an antibacterial and anticancer agent.
18.	Radonjic, V, et al. (author) Consumption of antihistamines in Serbia in the period 2011-2015 and the correlation with adverse drug reaction reports 2016 In: Vojnosanitetski pregled. - 0042-8450. ; 73:11, s. 1076-1077 Journal article (other academic/artistic)

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-18 of 18

Refine your search

Type of publication: journal article (13); conference paper (5)

Type of content: peer-reviewed (12); other academic/artistic (6)

Author/Editor: Godman, B (17); Kalaba, M (17); Laius, O (10); Sermet, C (10); Wettermark, B (10); Zara, C (9); show more...; Gustafsson, LL (8); Garuoliene, K (8); Bishop, I (7); Herholz, H (5); Berg, C. (5); Raschi, E (5); Vlahovic-Palcevski, ... (5); Furst, J (5); Joppi, R (5); De Ponti, F (5); Poluzzi, E (5); Sturkenboom, M (5); Schwabe, U (5); Wendykowska, K (4); Bucsics, A (4); Andersen, M (3); Malmstrom, RE (3); Bennie, M (3); Jan, S (3); Haycox, A (3); Campbell, S. (3); Finlayson, AE (3); Diogene, E (3); Markovic-Pekovic, V (3); Simoens, S (3); Selke, G (3); Wladysiuk, M (3); Burkhardt, T (3); McCullagh, L (3); Shrank, W (3); Teixeira, I (3); Jones, J. (2); Eriksson, I (2); Ofierska-Sujkowska, ... (2); Magnusson, E (2); Gulbinovic, J (2); Bonanno, PV (2); Zebedin-Brandl, E (2); Voncina, L (2); van Woerkom, M (2); Martikainen, JE (2); Spillane, S (2); Samaluk, V (2); Tilson, L (2); show less...

University: Karolinska Institutet (17); Umeå University (1)

Language: English (18)

Research subject (UKÄ/SCB): Medical and Health Sciences (2); Natural sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view